通化金馬(000766.SZ):子公司聖泰生物與金宏置業置換1.06億元資產
格隆匯5月19日丨通化金馬(000766.SZ)公佈,2019年國家陸續出台了新的藥品管理政策,對公司的全資子公司哈爾濱聖泰生物製藥有限公司(簡稱“聖泰生物”)的銷售產生了較大沖擊,部分產品在銷售渠道中產生了滯留現象。2020年初新冠肺炎疫情發生後,部分銷售客户出現經營困難,原來滯留在銷售渠道的產品出現回款遲緩問題,不僅增加了聖泰生物清收工作的人力和物力投入,也對聖泰生物的生產經營和經營業績產生不利影響。
為了解決這一問題,支持上市公司集中精力發展主業,支持上市公司開展新的營銷佈局,鼓勵上市公司開闢新的產學研業務,提升上市公司資產質量,增強上市公司抗風險能力,經公司控股股東北京晉商聯盟投資管理有限公司多方協調,2021年5月17日,聖泰生物與遼寧金宏日程置業有限責任公司(簡稱“金宏置業”)達成了《資產置換協議》。
該次聖泰生物擬置出資產為部分應收賬款,賬面淨值約1.06億元(聖泰生物部分應收賬款2020年末賬面餘額約2.66億元,已計提壞賬準備約1.60億元,2020年末賬面淨值約1.06億元,簡稱“擬置出資產”)。
該次聖泰生物擬置入資產為金宏置業持有的遼寧金宏日程商貿有限公司(簡稱“金宏商貿”)100%股權(簡稱“擬置入資產”),擬置入資產評估值約1.06億元。該公司核心資產為房屋資產,位於遼寧省營口市鮁魚圈區,用途為商住和商業服務,房屋建築面積為5641.02平方米,總層數為5層。除此之外,金宏商貿沒有其他經營活動。
擬置入資產與擬置出資產差額2.76萬元由金宏置業以現金方式支付給聖泰生物。該次置換的擬置入資產以2021年4月30日為基準日進行評估;擬置出資產以2020年12月31日為基準日進行審計。
該次資產置換完成後,金宏置業將擁有聖泰生物賬面淨值約1.06億元的應收賬款。公司下屬全資子公司聖泰生物將持有金宏商貿100%股權,金宏商貿名下的房產將作為公司北方營銷中心以及未來遼寧區域產學研基地使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.